Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

They're known to aid in blood sugar control and, now, weight loss — but, according to a sweeping new study, the popular GLP-1 ...

While it may seem strange that politics could impact the price of popular weight loss drugs, it is a definite possibility.

This is just a tiny glimpse of the data available to CivicScience clients. Discover more data. CivicScience has data on over ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...

Last Patient / Last Visit Completed Topline Data Readout Expected Later This Quarter CRANBURY, N.J., Feb. 6, 2025 /PRNewswire/ -- Palatin Technologies, Inc.

Inc. (NYSE American: PTN) has announced the completion of their Phase 2 clinical trial for an obesity treatment, marking a ...

After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.